Apellis Pharmaceuticals
Tracked across 3 events · 91 articles · First seen Apr 01, 2026 · Last active Aug 04, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Apellis Pharmaceuticals, Inc. is being sold to Biogen, Inc., with shareholders expected to receive $41.00 per share in cash and a contingent value right. Monteverde & Associates PC is investigating this sale.
Apr 01, 2026 · 47 articles
Business
Impact: Apellis Pharmaceuticals was acquired by Biogen earlier in March for approximately $5.6 billion, boosting Biogen's near-term revenue and expanding its presence in nephrology and immunology.
Jun 17, 2026 · 10 articles
Business
Impact: Mentioned as comparison for premium paid in acquisitions.
Jul 06, 2026 · 34 articles
ERGEN INTELLIGENCE
Track Apellis Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard